Clinical trial · no report yet · Phase 3
TAISHAN-302
A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer (TAISHAN-302)
- NCT06612151 ↗
- Active, not recruiting
- MediLink Therapeutics (Suzhou) Co., Ltd.
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 38 | |
| Podcasts | 4 | |
| YouTube | 3 |
The trial
ClinicalTrials.gov- Official title
- A Multicenter, Randomized, Controlled, Open-label, Phase III Study to Compare the Efficacy and Safety of YL201 Versus Topotecan Hydrochloride in Subjects With Relapsed Small Cell Lung Cancer
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Small Cell Lung Cancer
- Interventions
- YL201; topotecan hydrochloride for injection
- Arms
- YL201 · Experimental
- topotecan hydrochloride for injection · Active comparator
- Enrollment
- 438 (estimated)
- Primary outcomes
- To compare the OS of YL201 versus topotecan hydrochloride in subjects with relapsed SCLC.
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
- Start
- Dec 17, 2024
- Primary completion
- Dec 1, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06612151 · updated Sep 15, 2026
Publications
linked from the registry- Zhao Y, Liu H, Meng X, Liu Z, Yu Y, Zheng Y, Sun L, Yang R, Liu J, Zhao Y, Wu L, Yang L, Zhang Z, Li M, Zhang P, Zhang Y, Zhong H, Cui J, Huang Z, Yin Y, Li M, Tong F, Xue D, Lv D, Li X, Zhang X, Chin S, Cai J, Xue T, Huang Y, Zhao H, Zhang L; TAISHAN-302 Investigators. Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy. N Engl J Med. 2026 Sep 12. doi: 10.1056/NEJMoa2610229. Online ahead of print. PubMed 42734213